Why the study?
Does upstream abciximab reduce infarct size in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading?
Does upstream abciximab reduce infarct size in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading?
Upstream administration of abciximab does not reduce infarct size in STEMI patients presenting within 24 hours of symptom onset who have received a 600 mg clopidogrel loading dose.
No takes yet. Share an insight, caveat, or question.
No infarct size reduction with upstream abciximab after clopidogrel loading in STEMI; confirms limited role for routine GP IIb/IIIa inhibition before primary PCI.
Mehilli et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: